



CSN5 INFN new research project proposal (2023-2025)



CUPRUM-TTD


$^{67/64}\text{Cu}$ PRoduction and Use in Medicine – Target Technology Development

*J. Esposito on behalf of INFN/UNIPD/UNIFE/SCDC Hospital (Negrar, VR)/IOV/Padua Hospital/ICMATE-CNR
collaboration network*

New research project proposal to CSN5 INFN, July 1st, 2022

^{67}Cu and ^{64}Cu : a theranostic pair

Real Theranostic pairs




[C. Müller *et al.* J Nucl Med **2014**, 55:1658-64]

Radioisotope	Half-life [h]	Decay (%)	Main emissions (%) [KeV]
^{64}Cu	12.72	β^- (38.5%)	β^- 579 (38.5%)
		β^+ (17.5%)	β^+ 653 (17.5%)
		EC (44%)	γ 511 (35%) γ 1346 (0.5%)
^{67}Cu	61.83	β^- (100%)	β^- 562 (20%) β^- 468 (22%) β^- 377 (57%)
			γ 185 (49%) γ 91-93 (23%)

[NuDat 3.0]

* β^-/β^+ end-point energy

- Imaging (PET, SPECT)
- Therapy



[N.Herrero Álvarez *et al.*, ChemMedChem **2021**, 16: 2909 –2941]


State of the art and background experience on Cu radiometals

- ^{64}Cu is ALREADY commercially available and used in nuclear medicine for PET
- ^{64}Cu seems to provide excellent results also in THERAPY (even under simple $^{64}\text{CuCl}_2$)
- ^{67}Cu is a **promising radionuclide** for **Theranostic and Radioimmunotherapy**, as single isotope, or in pair with ^{64}Cu
- ^{67}Cu 's limiting factor: still lacking a **REGULAR availability worldwide**
- Only recently become available in US in enough quantities for **medical research applications (DOE-IP)**
- Production capability upon request ($\sim 1\text{-}2\text{ Ci/batch}$, 1 patient dose $\sim 100\text{ mCi} = 3.7\text{ GBq}$) @ ANL-LEAF via $^{68}\text{Zn}(\gamma, p)$ nuclear reaction (BNL through the $^{68}\text{Zn}(p, 2p)$)
- ^{67}Cu future supply in Europe: Goal both for ARRONAX and LARAMED

^{62}Zn 9.186 h $\epsilon = 100.00\%$	^{63}Zn 38.47 m $\epsilon = 100.00\%$	^{64}Zn $\geq 7.0\text{E}20\text{ y}$ 49.17% 2ϵ	^{65}Zn 243.93 d $\epsilon = 100.00\%$	^{66}Zn STABLE 27.73%	^{67}Zn STABLE 4.04%	^{68}Zn STABLE 18.45%	^{69}Zn 56.4 m $\beta^- = 100.00\%$	^{70}Zn $\geq 2.3\text{E}+17\text{ y}$ 0.61% $2\beta^-$
^{61}Cu 3.339 h $\epsilon = 100.00\%$	^{62}Cu 9.673 m $\epsilon = 100.00\%$	^{63}Cu STABLE 69.15%	^{64}Cu 12.701 h $\epsilon = 61.50\%$ $\beta^- = 38.50\%$	^{65}Cu STABLE 30.85%	^{66}Cu 5.120 m $\beta^- = 100.00\%$	^{67}Cu 61.83 h $\beta^- = 100.00\%$	^{68}Cu 30.9 m $\beta^- = 100.00\%$	^{69}Cu 2.85 m $\beta^- = 100.00\%$
^{60}Ni STABLE 26.223%	^{61}Ni STABLE 1.1399%	^{62}Ni STABLE 3.6346%	^{63}Ni 101.2 y $(p, n), (d, 2n)$ $\beta^- = 100.00\%$	^{64}Ni STABLE 0.9255%	^{65}Ni 2.175 h $\beta^- = 100.00\%$	^{66}Ni 54.6 h $\beta^- = 100.00\%$	^{67}Ni 21 s $\beta^- = 100.00\%$	^{68}Ni 29 s $\beta^- = 100.00\%$

Reactions indicated by arrows: $(n, p), (d, 2p), (\gamma, p), (p, 2p), (d, x), (p, \alpha), (\alpha, p)$



[<https://www.nndc.bnl.gov/nudat3/>]



PET/CT images collected after i.v. injection of $^{64}\text{CuCl}_2$ in patients with (a) prostate cancer, (b) cerebral tumor, (c) glioma.

$^{68}\text{Zn}(p,2p)^{67}\text{Cu}$ reaction production route

IAEA Technical Report Series No. 473 (2011)





$t_{\text{RNP} \geq 99\%}: 133-145 \text{ h}$

- In order to have a *pure* ^{67}Cu (RNP>99%) it is necessary to wait that ^{64}Cu decays \rightarrow lose $\approx 80\%$ of ^{67}Cu activity

^{67}Cu alternative production route: $^{70}\text{Zn}(p,\alpha)^{67}\text{Cu}$

IAEA Technical Report Series No. 473 (2011)





No experimental data available for $E_p > 35$ MeV

CoMe project (COpper xs MEasurement) : INFN


funded (Dotazioni CSN3_2016):

$^{70}\text{Zn}(p,x)^{67,64}\text{Cu}$ xs measurements in 45-70 MeV range



[G. Pupillo
Radiochim.
Acta 2022]

Main achievement held by COME prj



[L.Mou *et al.*
Molecules **2022**,
27: 1501]



“A method and a target for the production of ^{67}Cu ”

Mou, Pupillo, Martini, Pasquali



International Patent
n° WO 2019/220224 A1

	Irr. time (h)	^{67}Cu at EOB (MBq/ μA)	^{64}Cu at EOB (MBq/ μA)	^{61}Cu at EOB (MBq/ μA)	^{60}Cu at EOB (MBq/ μA)	$t_{99\%}$ (h)	^{67}Cu at $t_{99\%}$ (MBq/ μA)
^{68}Zn : 70–35 MeV	62	1240.1	6512.0	1140.1	26.5	145	244.1
	124	1859.4	6732.9	1140.1	26.5	136	404.8
	185	2165.2	6740.4	1140.1	26.5	133	487.5
^{70}Zn : 70–45 MeV	62	1751.7	7506.7	11.7	–	139	368.7
	124	2626.5	7761.4	11.7	–	131	604.8
	185	3058.5	7770.0	11.7	–	128	728.3
^{70}Zn : 70–55 MeV + ^{68}Zn : 55–35 MeV	62	1881.3	5825.0	40.0	0.0012	132	428.3
	124	2820.9	6022.6	40.0	0.0012	123	710.5
	185	3284.9	6029.3	40.0	0.0012	120	855.6


[De Nardo L. *et al.* Med
Phys. 2022;1–16]

CUPRUM-TTD (2023-2025) research project

In view of the next preclinical/clinical applications the goal of the current research proposal is therefore to develop beforehand a reliable technology aimed at **producing clinical-grade batches of ^{67}Cu - ^{64}Cu , on a routine basis by small medical cyclotrons.**

Main project GOALS:

- a) to acquire a robust and reliable target manufacturing technology to produce ^{70}ZnO target (and $^{\text{nat}}\text{Ni}$ targets for first ^{64}Cu yield batches from $^{64}\text{Ni}(\text{p},\text{n})^{64}\text{Cu}$ at a later stage);
- b) to design and construct proper targets, able to sustain beam power levels from medical cyclotrons (i.e. 18-20 MeV, 2/3 kW max);
- c) to develop/optimize the radiochemistry separation/purification methods: $\text{Zn} \rightarrow \text{Cu}$ to achieve a clinical-grade ^{67}Cu radionuclide;
- d) Implementation of *in-vitro* survival studies;
- e) Pre-clinical and clinical phantom imaging;
- f) to develop /optimize technology for the costly ^{70}Zn -enriched target material recovery.





INFN –LNL Target technology development

The starting point is the *know-how* gained for **metallic targets manufacturing** for medical cyclotrons (up to 1.0 kW/cm^2) successfully produced by a refined SPS (Spark Plasma Sintering) technique.

SPS (Spark Plasma Sintering) main advantages:


- ✓ Only **few minutes** for target fabrication compared to conventional sintering techniques
- ✓ Sintering of **high melting point materials** e.g metals Mo/Cr/Y or oxides
- ✓ **Bonding** between different materials (target material on backing) → no filler material in between
- ✓ Starting materials → **powder or foil**
- ✓ **100% efficiency** → very negligible losses of **isotope-enriched material** during manufacturing
- ✓ Possibility to produce easily **100-500 μm thickness pellet**




Au protective layer











Cr green pellet	D=10 mm, s=0.4mm (mass= ~200 mg)
Cu backing	D=23.7mm, s=1.7mm
Au protective layer in between (~25 μm) onto Cu disk	

The new SPS TT SINTER machine developed by INFN Pavia and PV University to be installed in the future LARAMED target laboratory



- machine design based upon LNL specifications



100Mo → 99mTc		nat,52Cr → 52Mn			Y → 89Zr
natMo pellet	100Mo pellet	natCr pellet	natCr pellet	52Cr pellet	natY foil
Cu backing	Cu backing Au protective layer	Nb backing	Cu backing Au protective layer	Nb backing Au protective layer	Nb backing
As prepared					
					

After irradiation with medical cyclotron


Heat power density during irradiation $\approx 1.1 \text{ kW/cm}^2$

SPS technique:
some past
results

Inverted magnetron deposition system developed for solid target production

The new, optimized, and alternative magnetron deposition setup as developed in the framework of METRICS (CSN5 2017-2021) – INTEF_TOTEM (2021-2022) projects.

Main idea: combine the advantages of Magnetron Sputtering (MS) deposition, along with target material improved usage or/and high recovering level.



Inverted magnetron: target (left view) and plasma (right view)



The vacuum system dedicated for inverted magnetron deposition test and future target production

CUPRUM-TTD proposed approach

- Development of a robust and reliable **target manufacturing technology** suitable for **irradiations at small medical proton cyclotrons** (e.g. up to 19 MeV like the ACSI TR19-300 of SCDCH - Negrar, VR) by using ^{nat}ZnO material.
 - **know-how acquisition to manufacture Zn oxides targets** (not metallic) in view of their **future use with higher power proton beams** like the SPES cyclotron (**Zn melting temp.: 1970 °C in oxide form, 419.5 °C in metal form**).
- Development of the **radiochemical procedure** for ^{nat}ZnO processing and extraction of the product ^{67}Cu (semi-automatic/automatic module).
- **Irradiation test @ HSCDC TR19/300 cyclotron** with first ^{70}ZnO targets produced and separation of ^{67}Cu product, QC studies, transport @ LNL and imaging @ LARIM lab (LNL), with the **micro-PET/SPECT/CT small animal scanner (collaboration with IOV)**.

CUPRUM-TTD proposed approach for **phase 1 project**:

$^{\text{nat}}\text{ZnO}$ target production for first irradiation tests @HSCDC

Study of the SPS process to obtain $^{\text{nat}}\text{ZnO}$ pellets;

- pellet main features -> **thickness 0.7 mm; mass about 500 mg**
- backing optimization (chemically resistant, high thermal conductivity):

Goal: max sustainable beam-on-target current determination

Bonding
Pellet+Backing mat.
(Possible approaches)

- (Nb, Ta, RG_C?) + Au : backing + coating; → **Spark Plasma Sintering (SPS)** process
- capsule holder (Al/Nb depending upon the needs) → **SPS process for $^{\text{nat}}\text{ZnO}$ pellet only**
- ZnO layer on selected backing → **Magnetron Sputtering**

Tests to be carried out :

- $^{\text{nat}}\text{ZnO}$ **layer characterization** with different techniques @ LNL: SEM, Energy Dispersive X-ray Spectroscopy (EDS) and profilometer (Surf. Treat. Lab.);
- $^{\text{nat}}\text{ZnO}$ **pellet mechanical resistance determination** (target upload/download from target station);
- **Thermomechanical tests resistance** (**19 MeV, 5-50 μA → ~0.1 – ~1.0 kW**)

Collaboration with : HSCDC (Negrar –VR)
INFN divisions involved: **LNL** (PV)

CUPRUM-TTD proposed approach for **phase 1 project**:

Target radiochemistry processing studies from $^{\text{nat}}\text{ZnO}$ targets @HSCDC

To develop the optimized $^{\text{nat}}\text{ZnO}$ targets dissolution/separation/purification system following the first irradiation tests

- **preliminary studies with $^{\text{nat}}\text{ZnO}$ pellets (cold tests)** to assess chemistry separation techniques (e.g. solvent-extraction, extraction chromatography etc.) – (**$^{\text{nat}}\text{Ni}$ pellets at a later stage**)
- **design of the reactor system configuration** when first $^{\text{nat}}\text{ZnO}/^{\text{nat}}\text{Ni}$ pellets/targets will be available
- **radiochemistry process optimization** (and system semi-automation) once the **first target samples (pellet + backing)** will be available

Tests to be carried out :

- **ICP-OES analysis** (in collaboration with UniFE);
- **gamma-spectrometry measurements and QC assessment** (in collaboration UniFE, UniMI @ LASA and HSCDC, Negrar-VR)

Goal: Development of the semi-automated ^6xCu isotopes separation/purification with minimum isotopic contaminants

Collaboration with : HSCDC (Negrar –VR)
INFN divisions involved: LNL, Fe, (PV), MI

CUPRUM-TTD proposed approach for **phase 2 project**:

first **^{70}ZnO -enriched** targets beam tests and ^{67}Cu batches production @HSCDC

(**^{70}Zn -enriched**) ZnO first target samples manufacturing

- a) selection of beam parameters suitable to yield small batches of ^{67}Cu based on theoretical calculations;
- b) Irradiation @ SCDC TR19/300 cyclotron: **$E_{\text{max}} = 19 \text{ MeV}$; $t_{\text{irr}} = ?$; $I_{\text{max}} = ?$**
 - [thermomechanical tests]
- c) Radiochemistry separation and purification tests of the ^{67}Cu samples produced;
 - [QC assessment]
 - [labeling tests with selected pharmaceutical products]

Experimental activities with ^{67}Cu thus produced:

- **Pharmacology lab** @UNIFE available for cellular *in-vitro* studies and with $^{67}\text{CuCl}_2$; (1 transport Negrar-UNIFE about 200 €)
- **SPECT phantom** imaging studies with ^{67}Cu with **preclinical and clinical gamma-camera** (@ LARIM and Padua Univ. Hospital)
- Possible *in-vivo* studies @LARIM (depending upon the completion of plants and re-starting activities)?

Goal: First ^{67}Cu *in-vitro* (*in vivo*?) imaging studies with known (or new) carrier molecules.

Collaboration with : HSCDC (Negrar –VR)
and IOV

INFN divisions involved: LNL, Fe, PD

CUPRUM-TTD proposed approach for **phase 2 project**: first **^{64}Ni -enriched** targets production for ^{64}Cu batches @ HSCDC

- (**^{64}Ni -enriched**) Ni first target samples manufacturing

SPS process to obtain first **^{64}Ni -enriched** and targets (Nb/Au/XX config.)

- ^{64}Cu : $^{64}\text{Ni}(p,n)^{64}\text{Cu} \rightarrow$ energy range 11.5 - 9 MeV \rightarrow target: $\sim 100\text{ }\mu\text{m}$ ^{64}Ni

To seek for alternative nuclear production routes...

$^{67}\text{Cu}/^{64}\text{Cu}$ (^{61}Cu) **with alpha-induced reactions @ARRONAX– Milan contribution**

- ^{61}Cu : $^{\text{nat}}\text{Ni}(\alpha,pxn)^{61,64,67}\text{Cu} \rightarrow$ energy range 70 – 8 MeV \rightarrow target: $\sim 20\text{ }\mu\text{m}$ $^{\text{nat}}\text{Ni}$
with the study of contaminants and the determination of RNP and SA
- ^{67}Cu : $^{64}\text{Ni}(\alpha,p)^{67}\text{Cu} \rightarrow$ energy range 30 – 15 MeV \rightarrow Thick Target Yield (TTY), using a thick target produced @LNL
- ^{61}Cu : $^{59}\text{Co}(\alpha,2n)^{61}\text{Cu} \rightarrow$ energy range 70 – 8 MeV \rightarrow target: $\sim 20\text{ }\mu\text{m}$ ^{59}Co with the study of contaminants

Collaboration with : HSCDC (Negrar –VR) and ARRONAX center (Nantes- FRA)

INFN divisions involved: LNL, MI, PV, PD


CUPRUM-TTD WP1: Target production and recovery

Target material

- ^{70}ZnO $T_m=1975^\circ\text{C}$ (25\$/mg)
- 1 target 500mg \rightarrow 4 target 41.6k€

Target production by SPS technique:

- Collaboration with Chem Dept UNIPV ($\text{ZnO} + \text{Ni}$ pellet)
- Support/holder investigation
- Target recovery and recycling (SPS)




Milestones and deliverables planned

WP1	
Sara Cisternino	LNL
Gabriele Sciacca	
Juan Esposito	
Giorgio Keppel	
Oscar Azzolini	UNIPV
Alisa Kotliarenko	
Umberto A. Tamburini	

M1: SPS technique development for ZnO target manufacturing (Nb/Au/ZnO kind);
M2: recovery process development for ^{nat}ZnO , and material powders characterization (SEM, EDS, profilometer);
M3: trial of target production with SPS technique starting from recovered ^{nat}ZnO ;
M4: SPS technique development for ^{nat}Ni target manufacturing (Nb/Au/Ni kind);

D1: 2/3 ZnO targets for surface analyses investigations (WP2);
D2: 5 ZnO targets for cold test chemical processing optimization (WP2);
D3: 2/3 ^{70}ZnO targets for production test;
D4: recovered ^{nat}ZnO powders.



CUPRUM-TTD WP2: Target radiochemistry processing

Separation and purification procedure development:

- cold tests ^{nat}ZnO
- ICP(OES) characterization @UNIFE

Automated module prototype development

- Purchase of modular units
- Hot test ^{nat}ZnO

Quality Control (QC) assessment on RCP:

- Hot tests ^{70}ZnO



Milestones and deliverables planned

WP2

Petra Martini

Alessandra Boschi

Teresa Ghirardi

Licia Uccelli

Lorenza Marvelli

Emiliano Cazzola

UNIFE

HSCDC

M5: development of separation and purification procedure using cold targets of ^{nat}ZnO

M6: development of a semi-automatic system for the separation and purification of Zn/Cu

M7: optimization and automation of ^{64}Cu separation


M8: productions tests of ^{67}Cu (^{64}Cu) by using enriched target and determination of the extraction yield and purity of the final product.

M9: QC analysis on ^{67}Cu (^{64}Cu) produced and isolated for pharmaceutical studies

D5: Zn/Cu separation and purification procedure

D6: semi-automatic module for the separation and purification of ^{67}Cu (^{64}Cu) from ZnO/Ni target

D7: ^{67}Cu (^{64}Cu) radiochemistry product quality assessment




CUPRUM-TTD WP3: Irradiation, γ -spectrometry and QC test

Irradiation runs on $^{nat}\text{ZnO}/^{nat}\text{Ni}$ for targets and radiochemical separation optimization

- selection of beam parameters suitable to yield small batches of $^{67}\text{Cu}/^{64}\text{Cu}$ based on theoretical calculations;
- 3 irradiation runs on ^{70}ZnO for first batches of ^{67}Cu ;
- 2 irradiations runs on ^{64}Ni for first batches of ^{64}Cu ;
- 4 irradiations runs on ^{nat}Ni and ^{59}Co with alpha particles for $^{61,64,67}\text{Cu}$ optimization production (xs meas. @ARRONAX)
- **2 irradiations runs on thick target of ^{64}Ni for TTY**
- **γ -spectrometry analysis for yield and RNP determination**




ACSI TR19 13-19
MeV, 300 μA
@Negrar Hospital



WP3		
Liliana Mou		
Gaia Pupillo	LNL	
Carlos Rossi Alvarez		
Juan Esposito		
Emiliano Cazzola	HSCDC	
Giancarlo Gorgoni		
Luciano Canton	INFN-PD	
Francesca Barbaro		
Simone Manenti	UNIMI (INFN-MI)	
Flavia Groppi		
Francesca Cagnetta		

Milestones and deliverables planned

M10: ^{nat}ZnO targets irradiation for thermomechanical stability tests
M11: ^{nat}ZnO targets irradiations for radiochemical separation optimization procedure
M12: 3 irradiations on ^{70}ZnO targets for ^{67}Cu batches production (2 irradiations on ^{64}Ni targets for ^{64}Cu).
M13: γ -spectrometry meas. to determine radiochemical procedure efficiency ($^{nat}\text{Zn}/^{nat}\text{Ni}$ targets)
M14: γ -spectrometry meas. to determine the activity and RNP of ^{67}Cu produced by irradiation of ^{70}Zn targets (^{64}Cu produced by ^{64}Ni targets and $^{61,64,67}\text{Cu}$ production by alpha beams on $^{nat}\text{Ni}/^{64}\text{Ni}/^{59}\text{Co}$ for xs determination)
D8: RNP of the produced $^{67}\text{Cu}/^{64}\text{Cu}$ radionuclides from $^{70}\text{ZnO}/^{64}\text{Ni}$
D9: xs measurements with alpha beams



WP4: RPs development, cellular, dosimetry and Imaging studies

Bifunctional ligand synthesis @LARIM


Radiolabeling with $^{64/67}\text{Cu}$ @LARIM

Characterization and stability evaluation of $^{64/67}\text{Cu}$ RPs
@LARIM @ICMATE-CNR

Evaluation of specific uptake and internalization in both
PSMA-positive and negative PCa cells


Cellular Dosimetry calculations @ INFN-PD

Preclinical and clinical Nuclear Imaging quality studies with
 $^{64/67}\text{Cu}$ @LARIM @Padova Hospital



• Milestones and deliverables planned

M15: synthesis of new conjugates
M16: Radiolabeling and stability studies
M17: Cellular uptake and dosimetry/survival calculations
M18: phantom imaging studies
D10: conjugates
D11: method to obtain Cu-PSMA RPs with high radiochemical yield
D12: Minimum activity and dimension of the tumor to obtain good imaging



WP4	
Laura Melendez-A.	IOV (INFN-LNL/Pd)
Alessandra Zorz	
Marta Paiusco	
Laura De Nardo	UNIPD (INFN-Pd/LNL)
Michele Bello	
Diego Cecchin	
Cristina Bolzati	CNR (INFN-Pd)
Giov. Di Domenico	UNIFE
Angelo Taibi	(INFN-FE)

Research units/collaborations taking part...



- Ferrara Branch
- Padua Branch
- Milan Branch



CUPRUM-TTD project 2023: FTE

[illegible]

CUPRUM-TTD project

INFN-Padua

PLANNED ACTIVITIES for 2023 and budget quotation (12 K€)

Item	What is needed	Estimated cost K€
In vitro studies to determine the percent of specific uptake and internalization in cells	Refrigerated shaker for incubating biological cultures	7.5
	^{64}Cu to radiolabel the developed Radiopharmaceuticals (2x10mCi)	3.0
	Consumables for cellular studies	1.0
Travels	Domestic travels Padua-Legnaro	0.5
TOTAL		12



Nessuna richiesta di servizi in sezione

Summary overall budget request CUPRUM FY2023

Sezioni / Lab	Missioni	Consumo/ Altri consumo	Trasporti	Manutenzione	Inventario	apparati	Sp- servizi	Tot. per sez/lab	FTE previsto
LNL	10.0	27.0				26.0		63.0	4.8
Fe	2.5	18.0						20.5	4.0
Pd	0.5	4.0			7.5			12.0	1.5
Mi	8.5	5.0	7.5	4.0				25.0	2.1
TOTALE	16.5	52.0	15.0	4.0		18.0		120.5	12.4

Budget request outlook CUPRUM-TTD FY2024 ~ 180 kEuro (circa 110 kEuro modulo automatico)
FY2025 ~ 70 kEuro

TOTAL BUDGET request (3yrs) ~ 370 kEuro

GRAZIE

CUPRUM-TTD project INFN-LNL

Item	What is needed	Estimated cost K€
<ul style="list-style-type: none"> ○ ZnO/Ni powder pellets production for target processing investigations ○ Preparation of samples with SPS technique @ PV university and first attempts with MS technique @LNL 	Equipment for target manufacturing and raw materials	5.0
	Chemical products for ZnO/Ni radiochemical separation	5.0
Manufacturing of first prototype ZnO/Ni targets	Nb backing + capsule procurement	5.0
	Gold foil for Cu target protecting layer	10.0
Equipment (lab. Furniture)	Muffola for ZnO recovery	3.0
	Hydraulic press for pellets preparation	7.5
	Quartz/borosilicate/Peek reactor vessels procurement	7.5
Upgrade inverted MS system	- dedicated vacuum chamber	3.0
	- Dedicated magnetic coil for cylindrical MS	5.0
	- Zn/ZnO target material	1.0
	- Cathode body for sputtering	1.0
Travels	Domestic travels Padua-Legnaro Padua-Ferrara, Padua-Pavia + presentations nat./intern. Congresses	10.0
TOTAL		63.0

CUPRUM-TTD project

INFN-Ferrara

Item	What is needed	Estimated cost K€
Early experiments on the proper separation and purification procedure using cold targets of ^{nat}ZnO and ^{nat}Ni	<p>Consumables: solvents, glassware, chemical products to optimize the radiochemistry method.</p> <p>Materials to assess the quality control of the extracted radionuclide.</p>	16.0
Service	Chemical analyses: ICP(OES) characterization @UNIFE	2.0
Travels	Domestic travels for meetings and experimental activity at the SCDCH (Negrar –VR) cyclotron unit	2.5
TOTAL		20.5

CUPRUM-TTD project

INFN-Milano

PLANNED ACTIVITIES for 2023 and budget quotation (25.0 k€)

Item	What is needed	Estimated cost k€
<ul style="list-style-type: none"> . ^{nat}Ni, ^{59}Co, ^{nat}Cu – commercially . ^{64}Ni targets produced by LNL/UNIPV for testing at ARRONAX facility with alpha beams <p>Spectrometry analyses of $^{67/64/61}\text{Cu}$ thus produced at the LASA lab</p>	<p>Targets purchase</p> <p>Spectrometry lab components</p>	5.0
Radioactive transport service	Nantes-MI; Pavia-Milano routes	7.5
Travels	<p>Domestic travels: Milano, Legnaro, Pavia, Verona</p> <p>International travels: Milano-ARRONAX for irradiations (2/3)</p>	8.5
Maintainace	Nitrogen; Radiochemical Lab.; Filters hoods	4.0
TOTAL		25.0